Process Chromatography: Five Decades of Innovation - - BioPharm International


Process Chromatography: Five Decades of Innovation

BioPharm International
Volume 20, Issue 10

Figure 6. Figure 6 shows the difference between the flow pattern of packed bed chromatography and membrane chromatography, which results in different frontal surface area to bed height ratios. The hydrodynamic properties presented by membrane adsorbers overcomes mass transfer limitations at low pressure but the lower total surface area dictates their use mainly in the removal of impurities or the capture of low concentration targets.
The history of membrane chromatography shows the immense progress that has been made since 1988, producing the diversity of membrane structures, surface chemistries, and configurations that are seen today. Commercial membranes have excellent manufacturing tolerances, which make them quite uniform in thickness and pore-size distribution, with any remaining unevenness negated by the use of stacks containing large numbers of sheets. For polishing applications, it has been shown that membrane chromatography has several clear advantages over resins, but in the future it will be necessary to address certain limitations that frustrate the wider adoption of this technology platform, particularly in large-scale industrial applications. These challenges include relatively low binding capacity and issues surrounding integrity testing. Although column packing is no longer necessary and diffusion-based integrity control is the state-of-the-art in membrane applications, additional functionality tests are mandatory to demonstrate even flow-distribution and the validity of scale-down experiments.66 Flow-distribution can be a significant challenge in membrane chromatography because of the large frontal area compared with the bed height (Figure 6). Fortunately, functionality tests are now becoming available and demonstrate that even at bed heights of less than 1 cm, membrane stacks are extremely reproducible and robust.

Disposable membrane chromatography can only live up to its expectations if its potential is not exaggerated and its use restricted to areas where membranes are clearly beneficial.

Beyond Chromatography?

It has been noted that "Process chromatography has the notoriety of being the single largest cost center in downstream processing" and Przybycien et al. have asked, "Is there life beyond packed bed chromatography?"67 Of the current alternatives, few technologies are likely to have a major impact on downstream processes, and process chromatography will remain the workhorse of the industry. However, protein precipitation with concomitant virus kill68 is a likely complement or alternative in protein purification, and plasmid DNA may be produced most efficiently by differential precipitation.69 Perfusion chromatography70 perhaps never lived up to its expectations, but the struggle to overcome mass transfer limitations in chromatography is currently being addressed by monoliths,71 which still suffer from low capacities for bulk protein purification. Displacement chromatography72 using low molecular weight displacers is of increasing interest now that commercial displacers are available. Because of its selectivity, affinity chromatography still shows promise for the future, particularly when alkaline-resistant, synthetic ligands are used instead of protein or peptide ligands.73

Various engineering solutions have been attempted over the years to address various challenges of unit operations. Examples include continuous (annular) chromatography and fluidized, rather than expanded beds, and integrating process steps into continuous processes. With improved engineering, radial flow columns provide an interesting opportunity to maximize adsorbent performance and reduce dilution during elution.74

A vision for the future of process chromatography is expressed by Jan-Christer Janson:

"In a world where not only the pure technical problems are important to the biochemical engineer but where regulatory constraints have become more and more an issue, a relevant vision for the future would be that systems—columns and media integrated—will be available that allow continuous scaling up for production and scale down for various process validation reasons, such as virus clearance studies and trouble shooting".75

Editor's note: This article is an expanded version of an article previously published in BioPharm International.

John Curling is the president of John Curling Consulting AB, Uppsala, Sweden, and is senior advisor to ProMetic BioTherapeutics, Inc., Gaithersburg, MD, +46 18 290620,
. Uwe Gottschalk, PhD, is vice president of purification technologies at Sartorius Stedim Biotech GmbH, Göttingen, Germany. Both are also members of BioPharm International's editorial advisory board.

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here